Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:22 pm Sale |
2024-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Citadel Advisors LLC | 422 0.000% |
-85,317 (-99.51%) |
Filing History |
| 2024-12-16 9:02 pm Unchanged |
2024-12-12 | 13D | Lyra Therapeutics, Inc. LYRA |
Perceptive Advisors LLC | 255,151 19.500% |
0 (Unchanged) |
Filing History |
| 2024-11-14 7:48 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Point72 Asset Management, L.P. | 0 0.000% |
-60,606 (Position Closed) |
Filing History |
| 2024-11-14 5:49 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 24,082 1.800% |
-86,989 (-78.32%) |
Filing History |
| 2024-11-14 5:48 pm Purchase |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Samsara BioCapital, L.P. | 65,635 4.980% |
10,030 (+18.04%) |
Filing History |
| 2024-11-14 4:53 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Nantahala Capital Management LLC | 14,042 1.061% |
-81,004 (-85.23%) |
Filing History |
| 2024-11-14 12:00 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Vestal Point Capital LP | 0 0.000% |
-60,000 (Position Closed) |
Filing History |
| 2024-08-15 6:31 pm Sale |
2024-08-14 | 13D | Lyra Therapeutics, Inc. LYRA |
Perceptive Advisors LLC | 255,151 19.500% |
-0 (-0.00%) |
Filing History |
| 2024-02-15 09:18 am Sale |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
PURA VIDA INVESTMENTS LLC | 32,277 3.060% |
-10,869 (-25.19%) |
Filing History |
| 2024-02-14 8:35 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 111,071 9.999% |
42,406 (+61.76%) |
Filing History |
| 2024-02-14 6:18 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Citadel Advisors LLC | 85,739 7.900% |
27,808 (+48.00%) |
Filing History |
| 2024-02-14 4:51 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Nantahala Capital Management LLC | 95,046 8.900% |
50,630 (+113.99%) |
Filing History |
| 2024-02-14 4:29 pm Unchanged |
2024-02-14 | 13D | Lyra Therapeutics, Inc. LYRA |
Perceptive Advisors LLC | 255,151 24.300% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:18 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Point72 Asset Management, L.P. | 60,606 5.800% |
606 (+1.01%) |
Filing History |
| 2024-02-13 4:34 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Vestal Point Capital LP | 60,000 5.700% |
60,000 (New Position) |
Filing History |
| 2023-11-16 5:00 pm Purchase |
2023-11-15 | 13G | Lyra Therapeutics, Inc. LYRA |
Point72 Asset Management, L.P. | 60,000 5.400% |
60,000 (New Position) |
Filing History |
| 2023-08-25 4:15 pm Purchase |
2022-04-12 | 13G | Lyra Therapeutics, Inc. LYRA |
Samsara BioCapital, L.P. | 55,605 5.600% |
55,605 (New Position) |
Filing History |
| 2023-06-12 5:23 pm Purchase |
2023-05-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Citadel Advisors LLC | 57,931 5.900% |
57,931 (New Position) |
Filing History |
| 2023-06-09 4:20 pm Purchase |
2023-05-31 | 13D | Lyra Therapeutics, Inc. LYRA |
NBVM GP LLC | 120,629 12.200% |
36,253 (+42.97%) |
Filing History |
| 2023-06-02 4:16 pm Purchase |
2023-05-31 | 13D | Lyra Therapeutics, Inc. LYRA |
Perceptive Advisors LLC | 255,151 25.800% |
72,217 (+39.48%) |
Filing History |